Characterization of the diarylether sulfonylester (-)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties (full – 2002) http://jpet.aspetjournals.org/content/302/1/359.long
BAY 38-7271: a novel highly selective and highly potent cannabinoid receptor agonist for the treatment of traumatic brain injury (abst – 2003)http://www.ncbi.nlm.nih.gov/pubmed/14647528
Neuroprotective and brain edema-reducing efficacy of the novel cannabinoid receptor agonist BAY 38-7271 (abst – 2003)http://www.ncbi.nlm.nih.gov/pubmed/14519516
Breakthrough in treatment of Traumatic Brain Injury: KeyNeurotek's clinical study reaches primary endpoint and shows significant increase in survival (news - 2009) http://www.drugs.com/clinical_trials...hows-8667.html
Early Survival of Comatose Patients after Severe Traumatic Brain Injury with the Dual Cannabinoid CB1/CB2 Receptor Agonist KN38-7271: A Randomized, Double-Blind, Placebo-Controlled Phase II Trial (abst – 2012) http://www.ncbi.nlm.nih.gov/pubmed/22696266
Cannabinoid Receptor Subtypes 1 and 2 Mediate Long-Lasting Neuroprotection and Improve Motor Behaviour Deficits After Transient Focal Cerebral Ischemia (abst – 2012) http://www.ncbi.nlm.nih.gov/pubmed/23069763
BAY 38-7271: a novel highly selective and highly potent cannabinoid receptor agonist for the treatment of traumatic brain injury (abst – 2003)http://www.ncbi.nlm.nih.gov/pubmed/14647528
Neuroprotective and brain edema-reducing efficacy of the novel cannabinoid receptor agonist BAY 38-7271 (abst – 2003)http://www.ncbi.nlm.nih.gov/pubmed/14519516
Breakthrough in treatment of Traumatic Brain Injury: KeyNeurotek's clinical study reaches primary endpoint and shows significant increase in survival (news - 2009) http://www.drugs.com/clinical_trials...hows-8667.html
Early Survival of Comatose Patients after Severe Traumatic Brain Injury with the Dual Cannabinoid CB1/CB2 Receptor Agonist KN38-7271: A Randomized, Double-Blind, Placebo-Controlled Phase II Trial (abst – 2012) http://www.ncbi.nlm.nih.gov/pubmed/22696266
Cannabinoid Receptor Subtypes 1 and 2 Mediate Long-Lasting Neuroprotection and Improve Motor Behaviour Deficits After Transient Focal Cerebral Ischemia (abst – 2012) http://www.ncbi.nlm.nih.gov/pubmed/23069763